Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23086688 | 0.98 | DPP4 (0.36) | ALDH1A1DPP4SCN9AGAA | |
| SCHEMBL19601432 | 0.93 | — | — | |
| SCHEMBL15354776 | 0.88 | — | — | |
| SCHEMBL21558067 | 0.79 | DPP4 (0.34) | DPP4 | |
| SCHEMBL17071833 | 0.78 | SLC6A2 (0.30) | — | |
| SCHEMBL12199945 | 0.78 | AOC2 (0.33) | — | |
| SCHEMBL21558089 | 0.76 | DPP4 (0.40) | ALDH1A1DPP4 | |
| SCHEMBL22263520 | 0.75 | — | — | |
| SCHEMBL24615835 | 0.75 | USP2 (0.37) | DPP4 | |
| SCHEMBL23899883 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040110768-A1 | Bombesin receptor antagonists | WARNER-LAMBERT COMPANY LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1334102-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333829-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002040475-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040022-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020058606-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058606-A1 | Treatment of sexual dysfunction | BRS3, GNRHR, VIPR2 | ALDH1A1 4719/4885DPP4 1479/4885SCN9A 2288/4885 |
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | ALDH1A1 3777/4885DPP4 1446/4885SCN9A 484/4885 |
| US-20040110768-A1 | Bombesin receptor antagonists | NPY1R, BDKRB1, NPY2R | ALDH1A1 4738/4885DPP4 4112/4885SCN9A 483/4885 |
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | ALDH1A1 3614/4885DPP4 396/4885SCN9A 2465/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | ALDH1A1 3614/4885DPP4 396/4885SCN9A 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.